Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58274 | 0.77 | MAP4K4 (1.00) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL867042 | 0.77 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL25776743 | 0.77 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL864036 | 0.77 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL4818798 | 0.77 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL14044627 | 0.77 | MAP4K4 (0.60) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| Hydrochloric Acid SCHEMBL15019896 | 0.75 | MAP4K4 (0.96) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| Hydrochloric Acid SCHEMBL30590600 | 0.75 | MAP4K4 (0.96) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| Iodide SCHEMBL30111106 | 0.75 | MAP4K4 (0.96) | MAP4K4PIK3CAPDE10AEGFRKDR | |
| SCHEMBL21855919 | 0.74 | MAP4K4 (0.34) | MAP4K4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | SYNGENE INTERNATIONAL LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| WO-2015148746-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PIK3CA 1054/4885PDE10A 815/4885 |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | MAP4K4 1329/4885PIK3CA 1208/4885PDE10A 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.